Home » Stocks » Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc. (DRNA)

Stock Price: $19.00 USD -0.16 (-0.84%)
Updated Aug 14, 2020 4:00 PM EDT - Market closed
After-hours: $18.99 -0.01 (-0.07%) Aug 14, 4:11 PM

Stock Price Chart

Key Info

Market Cap 1.41B
Revenue (ttm) 89.59M
Net Income (ttm) -124.77M
Shares Out 74.46M
EPS (ttm) -1.76
PE Ratio n/a
Forward PE 28.49
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $19.00
Previous Close $19.16
Change ($) -0.16
Change (%) -0.84%
Day's Open 19.22
Day's Range 18.76 - 19.79
Day's Volume 364,489
52-Week Range 11.75 - 27.68

More Stats

Market Cap 1.41B
Enterprise Value 765.33M
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 74.46M
Float 57.56M
EPS (basic) -1.77
EPS (diluted) -1.76
FCF / Share 3.06
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 16.02%
Payout Ratio n/a
Shares Short 4.32M
Short Ratio 7.01
Short % of Float 5.57%
Beta 1.71
PE Ratio n/a
Forward PE 28.49
P/FCF Ratio 6.24
PS Ratio 15.79
PB Ratio 9.66
Revenue 89.59M
Operating Income -132.69M
Net Income -124.77M
Free Cash Flow 226.65M
Net Cash 649.39M
Net Cash / Share 8.72
Gross Margin -95.36%
Operating Margin -148.11%
Profit Margin -139.30%
FCF Margin 252.98%
ROA -15.16%
ROE -77.42%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 10
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$34.44*
(81.26% upside)
Low
25.0
Current: $19.00
High
46.0
Target: 34.44
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue23.906.181.03-0.18--7.027.91
Revenue Growth287.05%499.61%------11.29%-
Gross Profit23.906.181.03-0.18--7.027.91
Operating Income-128-90.35-60.74-59.75-63.03-45.10-17.38-9.25-7.61
Net Income-120-88.85-60.20-59.51-62.84-47.94-18.52-10.12-8.56
Shares Outstanding68.4355.6221.9220.7220.3216.070.030.030.03
Earnings Per Share-1.76-1.60-3.66-2.87-3.09-3.00-709.57-516.00-492.76
Operating Cash Flow-0.6918.30-45.33-48.75-48.80-34.76-10.94-15.74-8.87
Capital Expenditures-6.35-0.36-0.13-0.45-1.13-2.01-0.41-0.12-0.50
Free Cash Flow-7.0417.94-45.46-49.20-49.93-36.78-11.36-15.86-9.37
Cash & Equivalents34930311445.8794.6196.1246.603.6722.49
Total Debt20.14-----4.858.8011.57
Net Cash / Debt32930311445.8794.6196.1241.75-5.1310.92
Assets59740912151.2510010449.7910.1924.64
Liabilities44520819.9210.049.005.278.4710.6615.12
Book Value15220110141.2191.0298.34-68.92-64.72-50.63
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Dicerna Pharmaceuticals, Inc.
Country United States
Employees 187
CEO Douglas M. Fambrough

Stock Information

Ticker Symbol DRNA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: DRNA
IPO Date January 30, 2014

Description

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiometabolic diseases. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise DCR-A1AT programs; and a program for the treatment of neurodegeneration and pain. Dicerna Pharmaceuticals, Inc. has strategic collaborations with Novo Nordisk A/S, Roche, Eli Lilly and Company, Alnylam Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.